180 related articles for article (PubMed ID: 11392221)
1. [Bladder wall permeability to to topically administered cisplatin].
Zyrianov BN; Selivanov SP
Urologiia; 2000; (5):28-30. PubMed ID: 11392221
[TBL] [Abstract][Full Text] [Related]
2. [Fundamental studies on intravesical instillation of cis-diamminedichloroplatinum for treatment of urinary bladder tumors. II. On the effects of intravesical instillation of cis-diamminedichloroplatinum in bladder cancer patients].
Hirao Y; Iwai A; Moriya A; Matsuki H; Yoshida Y; Komada S; Sasaki K; Kubota K; Sanma S; Babaya K
Hinyokika Kiyo; 1985 Sep; 31(9):1565-73. PubMed ID: 4083214
[TBL] [Abstract][Full Text] [Related]
3. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells.
Derycke AS; Kamuhabwa A; Gijsens A; Roskams T; De Vos D; Kasran A; Huwyler J; Missiaen L; de Witte PA
J Natl Cancer Inst; 2004 Nov; 96(21):1620-30. PubMed ID: 15523091
[TBL] [Abstract][Full Text] [Related]
4. [Study on platinum concentration in internal iliac venous blood after iliac artery cisplatin infusion for invasive bladder cancer].
Okada H; Oguchi N; Uchida J; Mikami O; Matsuda T
Hinyokika Kiyo; 1999 Feb; 45(2):145-8. PubMed ID: 10212790
[TBL] [Abstract][Full Text] [Related]
5. [The p53 positivity in non-tumor mucosa in patients with superficial urinary bladder cancer].
Soukup V; Babjuk M; Dusková J; Pesl M; Szakácsova M; Zámefnik L; Dvorácek J
Cas Lek Cesk; 2007; 146(1):63-7. PubMed ID: 17310587
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the platinum analog [Pt(cis-dach)(DPPE)-2NO3] on histocultured human patient bladder tumors and cancer cell lines.
Chang SG; Jung JC; Rho YS; Huh JS; Kim JI; Hoffman RM
Anticancer Res; 1996; 16(6B):3423-8. PubMed ID: 9042201
[TBL] [Abstract][Full Text] [Related]
11. Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration.
Jacobi GH; Kurth KH
J Urol; 1980 Jul; 124(1):34-7. PubMed ID: 7411716
[No Abstract] [Full Text] [Related]
12. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy with cisplatin and cyclophosphamide and maintenance chemotherapy with doxorubicin and 5-FU in advanced urinary bladder tumors.
Sulkes A; Fuks Z
Cancer Treat Rep; 1983 Feb; 67(2):200-1. PubMed ID: 6681734
[No Abstract] [Full Text] [Related]
14. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
15. The topical use of misonidazole in bladder cancer.
Awwad HK; Abd El Moneim H; Abd El Baki H; Omar S; El Merzabani M; Farag HI
Prog Clin Biol Res; 1983; 132D():305-16. PubMed ID: 6634802
[TBL] [Abstract][Full Text] [Related]
16. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
17. Determination of hypericin in human plasma by high-performance liquid chromatography after intravesical administration in patients with transitional cell carcinoma of the bladder.
Kamuhabwa AA; Di Mavungu JD; Baert L; D'Hallewin MA; Hoogmartens J; de Witte PA
Eur J Pharm Biopharm; 2005 Apr; 59(3):469-74. PubMed ID: 15760727
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
19. Is intravesical chemotherapy for superficial bladder cancer still justified?
Okeke AA; Probert JL; Gillatt DA; Schwaibold H
BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
[No Abstract] [Full Text] [Related]
20. [Platinum concentrations in human tissue after administration of cisplatin].
Tochigi T; Ono K; Yoshikawa K; Hoshi S; Orikasa S; Imai Y
Gan To Kagaku Ryoho; 1988 Feb; 15(2):269-75. PubMed ID: 3341789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
